The current status of infrastructure for monitoring the efficacy of antimalarial therapeutics in Zambia

2020 ◽  
Author(s):  
Lungwani Muungo

Background. Sub-Saharan countries have experienced centuries of high morbidity and mortality due to malaria. In addition to insecticide-treated mosquito nets and indoor residual spraying, modern antimalarial medicines have been developed to reduce disease prevalence, although the emergence of drug-resistant strains has compromised their efficacy. The purpose of this study was to evaluate the current status of malaria diagnosis and treatment and to monitor the therapeutic efficacy of antimalarial drugs.Materials and Methods. A descriptive cross-sectional survey was conducted from 2011 to 2013 at 10 district hospitals in Zambia designated as malaria sentinel sites as well as at the National Malaria Control Centre. District medical officers at each site completed interview questionnaires.Results. Although basic infrastructure necessary for monitoring antimalarial drug resistance (such as laboratory, dispensary, admission ward, database unit, administration offices, bed space, examination and emergency rooms) was present at all sites, there was a shortage of licensed healthcare personnel. At some sites, antimalarial drugs were prescribed for malaria-like symptoms without diagnostic confirmation by blood smear. There was no regular monitoring of antimalarial drug resistance: only one trial was conducted among all sites in the previous 24 months.Conclusion. A lack of antimalarial drug resistance monitoring might be associated with personnel and funding shortages. Additional financial support would be necessary to avoid the development and spread of drug-resistant malaria in Zambia.

2010 ◽  
Vol 42 (1) ◽  
pp. 22-32 ◽  
Author(s):  
Valérie Andriantsoanirina ◽  
Didier Ménard ◽  
Luciano Tuseo ◽  
Rémy Durand

2021 ◽  
Vol 12 ◽  
Author(s):  
Alexandra T. Roux ◽  
Leah Maharaj ◽  
Olukunle Oyegoke ◽  
Oluwasegun P. Akoniyon ◽  
Matthew Adekunle Adeleke ◽  
...  

Malaria is a great concern for global health and accounts for a large amount of morbidity and mortality, particularly in Africa, with sub-Saharan Africa carrying the greatest burden of the disease. Malaria control tools such as insecticide-treated bed nets, indoor residual spraying, and antimalarial drugs have been relatively successful in reducing the burden of malaria; however, sub-Saharan African countries encounter great challenges, the greatest being antimalarial drug resistance. Chloroquine (CQ) was the first-line drug in the 20th century until it was replaced by sulfadoxine–pyrimethamine (SP) as a consequence of resistance. The extensive use of these antimalarials intensified the spread of resistance throughout sub-Saharan Africa, thus resulting in a loss of efficacy for the treatment of malaria. SP was replaced by artemisinin-based combination therapy (ACT) after the emergence of resistance toward SP; however, the use of ACTs is now threatened by the emergence of resistant parasites. The decreased selective pressure on CQ and SP allowed for the reintroduction of sensitivity toward those antimalarials in regions of sub-Saharan Africa where they were not the primary drug for treatment. Therefore, the emergence and spread of antimalarial drug resistance should be tracked to prevent further spread of the resistant parasites, and the re-emergence of sensitivity should be monitored to detect the possible reappearance of sensitivity in sub-Saharan Africa.


2019 ◽  
Vol 101 (4) ◽  
pp. 799-802 ◽  
Author(s):  
Ross M. Boyce ◽  
Nicholas Brazeau ◽  
Travis Fulton ◽  
Nick Hathaway ◽  
Michael Matte ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document